Steve Kaldor believes in “personalized medicine,” depending on your definition.
If it involves the idea of delivering customized treatment to individual patients, Kaldor is skeptical of the economics. But his Quanticel Pharmaceuticals Inc., a young San Francisco company emerging with backing from Versant Ventures and a $45 million deal with Celgene Inc., is readying a technology that at least could narrow the odds for cancer patients.
Spun out of the work of Stanford University scientists Stephen Quake and Michael Clarke, Quanticel’s technology allows researchers to analyze in “exquisite detail” individual cells from tumor samples, Kaldor said. That could give unique insight into how to target cancer-fighting drugs as well as speed up clinical trials and identify novel new drugs.